Do Ozempic and similar GLP-1 drugs increase the risk of a rare form of vision loss?
Confidence as of July 1, 2026
6 claims5 open questions
Our take
Several studies link GLP-1 drugs to a rare optic-nerve stroke. An association is not the same as proof they cause it.
Why we say this
JAMA Ophthalmology, 2024
Higher NAION incidence among semaglutide users than matched controls.
JAMA Ophthalmology editorial, 2024
Observational studies can show association; they cannot settle causation.
FDA label, 2026
Ozempic prescribing information does not currently list NAION as an established adverse reaction.
This is not a claim of absolute truth. Read the whole story for more context.
as of July 1, 2026
Reports linking Ozempic (semaglutide) and other GLP-1 drugs (formally, GLP-1 receptor agonists) to blindness have drawn widespread attention. The current evidence does not establish that these drugs cause blindness, but several observational studies have reported an association with non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of sudden optic nerve injury. Separately, semaglutide has a longer-standing warning about diabetic retinopathy complications — a different eye problem that public discussion sometimes conflates with NAION. We are tracking whether accumulating evidence supports a causal relationship between GLP-1 drugs and NAION, or whether the observed association is explained by underlying risk factors such as diabetes and vascular disease.
Where things stand
Multiple independent observational studies have reported an association between GLP-1 drugs and NAION, but none can establish causation. Researchers continue to investigate whether the relationship reflects a drug effect, characteristics of patients prescribed these medications, or other confounding factors. Regulators and ophthalmologists are monitoring the evidence, but no consensus has concluded that semaglutide causes NAION. Other ocular concerns — especially diabetic retinopathy complications noted in clinical trials and labeling — are tracked here as a separate question from the NAION signal.
Soon you'll be able to follow a story and get notified when the evidence changes.
Confidence
as of July 1, 2026We are cautiously confident that there is a real signal worth investigating because multiple independent observational studies have reported elevated rates of NAION among GLP-1 drug users. However, the existing evidence remains observational and cannot determine causation.
This is our best read given the published evidence we have reviewed — not a claim of absolute truth.
Open questions
Does semaglutide itself increase the risk of NAION?
Current studies are observational and cannot fully separate drug effects from patient risk factors.
Are some GLP-1 drugs associated with higher risk than others?
Different drugs may have different pharmacology or prescribing populations.
Which patients are most susceptible?
Understanding individual risk could improve prescribing decisions without unnecessarily discouraging treatment.
What biological mechanism could explain the association?
A plausible mechanism would strengthen evidence for causality.
Are other reported ocular risks — especially diabetic retinopathy complications — related to the NAION signal, or separate questions?
Public discussion of “Ozempic blindness” often conflates sudden optic-nerve injury with retinopathy and other vision changes that have different evidence and mechanisms.
What would change our mind
- Large prospective studies finding no increased NAION risk after careful adjustment for diabetes severity and vascular risk factors.
- Multiple independent studies consistently reproducing the association across different populations.
- Mechanistic evidence demonstrating how GLP-1 drugs could directly contribute to optic nerve injury.
- Updated regulatory conclusions based on substantially larger bodies of evidence.
Timeline — How we got here
6 updates · append-onlyNew evidenceAAO and NANOS reject a blanket recommendation to stop semaglutide after NAION
Responding to the EMA advice, the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society said they do not support a blanket recommendation that all patients stop semaglutide if NAION is diagnosed, citing potential serious risks to overall health from discontinuation. They advised shared decision-making among the patient and care team, noting that available evidence shows a possible link but has not established that semaglutide causes NAION, and that absolute risk remains low.
Claims & evidence
Each claim is tracked separately — not a single verdict.Several observational studies have reported an association between GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy (NAION).
Evidence basis- July 3, 2024Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Retrospective study reporting increased incidence of NAION among semaglutide users compared with matched controls.
- May 1, 2026Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology
Professional society summarizes the observational findings — that there is a possible link between semaglutide and NAION — while emphasizing they do not establish causation.
Current evidence does not establish that Ozempic or semaglutide causes NAION.
Evidence basis- July 3, 2024Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Observational studies identify an association but cannot determine causality.
- May 1, 2026Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology
Experts caution patients not to discontinue medication based solely on the observational findings.
NAION is a rare condition, even among patients taking GLP-1 drugs.
Evidence basis- September 14, 2025Nonarteritic Anterior Ischemic Optic Neuropathy
The annual incidence of NAION in the United States is estimated to be 2.3 to 10.3 cases per 100,000 individuals aged 50 or older.
- July 3, 2024Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Absolute numbers of NAION events remained small.
People with diabetes already have a higher baseline risk of NAION than the general population.
Evidence basis- January 1, 2023Non-Arteritic Anterior Ischemic Optic Neuropathy
Diabetes mellitus is an established vascular risk factor for NAION.
- January 1, 2023NAION: Diagnosis and Management
"The best-known risk factors for NAION are vasculopathic, including diabetes, smoking, hypertension, and hypercholesterolemia."
The FDA-approved prescribing information for Ozempic does not currently identify NAION as an established adverse reaction.
Evidence basis- May 1, 2026Ozempic Prescribing Information
Current labeling does not list NAION as an established adverse reaction.
Semaglutide has a separate, longer-standing concern about diabetic retinopathy complications that is distinct from the more recent NAION signal.
Evidence basis- September 15, 2016Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Diabetic retinopathy complications occurred in 3.0% of patients in the semaglutide group and 1.8% in the placebo group (hazard ratio, 1.76); authors noted rapid glucose lowering as a possible explanation while not ruling out a direct drug effect.
- May 1, 2026Ozempic Prescribing Information
Warns that diabetic retinopathy complications were reported in a clinical trial and that patients with a history of diabetic retinopathy should be monitored; rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy.
What this doesn’t establish
Claims commonly associated with this story that the available evidence does not establish. Confirming a narrow fact here is not confirmation of the broader narrative around it. As such, these claims are not included in the claims bar above.
Ozempic (semaglutide) or other GLP-1 drugs cause NAION, the rare form of vision loss.
Evidence basis- February 1, 2025Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Observational studies identify an association but cannot determine causality; a causal relationship has not been established.
- May 1, 2026Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology
The society emphasizes the findings do not establish causation and cautions patients not to discontinue medication based on them.
Help improve this story
Point us at a source, a mistake, or a framing problem. Every submission is reviewed by a human before anything changes — this is not a vote on what’s true.
Confidence last reviewed July 1, 2026. Updates are append-only; nothing here is edited silently.
Soon you'll be able to follow a story and get notified when the evidence changes.